Airway microbiome‐derived IAA mitigates COPD pathophysiology by reducing neutrophilic inflammation, epithelial apoptosis, emphysema, and lung function decline, via macrophage–epithelial cell crosstalk mediated by IL‐22 signaling [23]. Here, IL22 is linked to chronic obstructive pulmonary disease.